Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NERV

Minerva Neurosciences Inc

Mar 10 • 04:00PM ET

7.94

-0.06 -0.75 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD SAGE NBIX AXSM VRTX BMRN CYTK ALKS UTHR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.85	Insider Own	17.41%	Shs Outstand	43.27M	Perf Week	15.74%
Market Cap	343.60M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	0.00%	Shs Float	35.74M	Perf Month	65.42%
Enterprise Value	391.21M	PEG	-	EPS next Q	-0.30	Inst Own	54.38%	Short Float	1.23%	Perf Quarter	106.77%
Income	-14.03M	P/S	-	EPS this Y	-937.74%	Inst Trans	32.61%	Short Ratio	4.14	Perf Half Y	265.90%
Sales	0.00M	P/B	-	EPS next Y	50.19%	ROA	-39.57%	Short Interest	0.44M	Perf YTD	97.51%
Book/sh	-4.94	P/C	27.73	EPS next 5Y	-	ROE	-	52W High	12.46 -36.28%	Perf Year	405.73%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	- -	ROIC	-55.18%	52W Low	1.15 590.43%	Perf 3Y	376.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	19.49% 12.04%	Perf 5Y	-67.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-323.61%	Oper. Margin	-	ATR (14)	0.72	Perf 10Y	-82.18%
Dividend Ex-Date	-	Quick Ratio	4.87	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.95	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.87	EPS Q/Q	-112.19%	SMA20	21.35%	Beta	-0.33	Target Price	4.50
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	51.89%	Rel Volume	3.53	Prev Close	8.00
Employees	8	LT Debt/Eq	-	Earnings	Nov 05 BMO	SMA200	141.32%	Avg Volume	105.80K	Price	7.94
IPO	Jul 01, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	356,361	Change	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$20 → $10
May-14-20	Initiated	BTIG Research	Buy	$23
Oct-02-19	Reiterated	Chardan Capital Markets	Buy	$17
Sep-25-19	Initiated	Chardan Capital Markets	Buy	$17
Sep-18-19	Initiated	William Blair	Outperform
May-31-19	Initiated	H.C. Wainwright	Buy
Sep-01-17	Initiated	Citigroup	Buy	$11
Mar-06-17	Resumed	Jefferies	Buy	$17
May-12-16	Resumed	Jefferies	Buy

Mar-04-26 07:00AM	Minerva Neurosciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Feb-04-26 02:07AM	Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia (MarketBeat) -5.27%
Jan-26-26 07:00AM	Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 (GlobeNewswire)
Nov-19-25 08:30AM	Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors (GlobeNewswire)
Nov-05-25 07:40AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Oct-21-25 08:00AM	Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved (GlobeNewswire) +140.98%
Aug-14-25 04:43PM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance) +25.35%
04:35PM	Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results (GlobeNewswire)
May-13-25 07:30AM	Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
07:22AM	Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press Finance)
Feb-25-25 07:32AM	Minerva Neurosciences: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-05-24 07:40AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
01:53PM	Loading…
Aug-06-24 01:53PM	NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024 (InvestorPlace) +5.00%
07:34AM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-06-24 12:00PM	Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-01-24 01:53PM	NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024 (InvestorPlace)
07:43AM	Minerva Neurosciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-27-24 08:11AM	US FDA declines to approve Minerva Neurosciences' schizophrenia drug (Reuters) -58.82%
08:00AM	Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia (GlobeNewswire)
06:31AM	Minerva schizophrenia drug rejected by FDA (BioPharma Dive)
Feb-22-24 07:41AM	Minerva Neurosciences: Q4 Earnings Snapshot (Associated Press Finance) -17.61%
07:00AM	Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates (GlobeNewswire)
Nov-07-23 07:47AM	Minerva Neurosciences: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
07:40AM	Loading…
Aug-01-23 07:40AM	Minerva Neurosciences: Q2 Earnings Snapshot (Associated Press Finance) +9.15%
07:30AM	Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates (GlobeNewswire)
Jun-28-23 08:30AM	Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market (GlobeNewswire) +69.27%
Jun-09-23 09:55AM	Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-18-23 12:00PM	What Makes Minerva Neurosciences (NERV) a New Buy Stock (Zacks) +10.15%
May-15-23 09:57PM	Q1 2023 Minerva Neurosciences Inc Earnings Call (Thomson Reuters StreetEvents) -11.42% -12.42%
07:40AM	Minerva Neurosciences: Q1 Earnings Snapshot (AP Finance)
07:30AM	Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates (GlobeNewswire)
May-10-23 08:00AM	Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) +13.68%
May-08-23 08:30AM	Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023 (GlobeNewswire)
May-01-23 07:00AM	Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) +34.29%
Mar-10-23 02:24AM	Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.01%
Mar-08-23 11:12PM	Q4 2022 Minerva Neurosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.65%
07:30AM	Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates (GlobeNewswire)
Mar-01-23 08:30AM	Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 (GlobeNewswire)
Dec-29-22 10:18AM	Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA (Zacks) +5.59%
05:30AM	The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application (American City Business Journals)
Dec-28-22 08:00AM	Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire) -39.15%
Nov-09-22 08:00AM	Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +8.85%
Nov-02-22 08:30AM	Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022 (GlobeNewswire) +6.52%
Oct-20-22 11:28AM	Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More (Zacks)
Oct-17-22 09:18AM	Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate (Benzinga) -69.55%
08:51AM	Minerva Neurosciencs to request meeting with FDA about schizophrenia drug (MarketWatch)
08:30AM	Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Sep-09-22 04:05PM	Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Aug-31-22 06:25PM	The 5 Bestand 5 WorstNasdaq Stocks in August (Barrons.com) -14.35% -14.18%
Aug-23-22 12:38PM	Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up (Zacks)
Aug-22-22 08:00AM	Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia (GlobeNewswire) +47.83%
Aug-12-22 09:55AM	Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher (Zacks)
Aug-09-22 08:00AM	Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -23.89%
Jun-22-22 08:58AM	Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation (Simply Wall St.) -5.26%
May-04-22 08:30AM	Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Apr-07-22 09:57AM	Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study (Zacks)
08:30AM	Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia (GlobeNewswire)
Mar-21-22 09:52AM	Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder (Zacks)
Mar-01-22 09:05AM	Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Feb-28-22 08:30AM	Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin (GlobeNewswire)
Dec-01-21 07:44AM	Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth? (Simply Wall St.) -6.82%
Nov-08-21 08:45AM	Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-03-21 08:30AM	Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission (GlobeNewswire)
Nov-01-21 08:30AM	Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 (GlobeNewswire)
Oct-11-21 08:30AM	Minerva Neurosciences Announces Promotion of Geoff Race to President (GlobeNewswire)
Oct-01-21 07:00AM	15 Stocks Moving in Friday's Pre-Market Session (Benzinga) -9.20%
Sep-30-21 10:32AM	Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations (Benzinga)
08:30AM	Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia (GlobeNewswire)
Sep-27-21 08:30AM	Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options (Zacks)
Sep-08-21 08:30AM	Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development (GlobeNewswire)
Aug-02-21 08:55AM	Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jul-26-21 03:01PM	Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:30AM	Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 (GlobeNewswire)
Jun-10-21 08:30AM	Minerva Neurosciences to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-04-21 05:20AM	What Type Of Shareholders Own The Most Number of Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares? (Simply Wall St.)
May-28-21 08:00AM	Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-19-21 06:19AM	Minerva Neurosciences (NERV) Enters Overbought Territory (Zacks) -9.69%
May-17-21 07:57AM	Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't? (Zacks) +13.65%
May-13-21 09:01AM	The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen (Zacks)
May-12-21 02:35PM	Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More (Zacks) +15.70%
10:03AM	Minerva (NERV) Soars on Promising Schizophrenia Study Data (Zacks)
08:30AM	Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining? (PR Newswire)
07:30AM	Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
07:20AM	Minerva Shares Soar on Positive Schizophrenia Drug Trial (TheStreet.com)
06:59AM	Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning (Benzinga)
06:45AM	Minerva Neurosciences, Inc. to Host Earnings Call (ACCESSWIRE)
May-11-21 04:15PM	Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension (GlobeNewswire)
May-05-21 05:10PM	Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021 (GlobeNewswire) -5.46%
Apr-07-21 08:46AM	Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? (Zacks)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Federated Hermes Kaufmann Fund	10% Owner	Mar 10 '26	Proposed Sale	8.00	12,456	99,648	Mar 10 05:20 PM
Federated Hermes Kaufmann Smal	10% Owner	Mar 10 '26	Proposed Sale	8.00	264,615	2,116,920	Mar 10 05:15 PM
Federated Hermes Kaufmann Fund	10% Owner	Mar 10 '26	Proposed Sale	8.00	424,278	3,394,224	Mar 10 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NERV

Minerva Neurosciences Inc

Upgrade your FINVIZ experience